Phillips A - Search Results

1

Factors Associated With Persistence of Plasma HIV-1 RNA During Long-term Continuously Suppressive Firstline Antiretroviral Therapy.

Ruggiero A, Cozzi-Lepri A, Beloukas A, Richman D, Khoo S, Phillips A, Geretti AM; ERAS Study Group. Ruggiero A, et al. Among authors: phillips a. Open Forum Infect Dis. 2018 Feb 3;5(2):ofy032. doi: 10.1093/ofid/ofy032. eCollection 2018 Feb. Open Forum Infect Dis. 2018. PMID: 29507867 Free PMC article.

2

HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.

Cozzi Lepri A, Pezzotti P, Dorrucci M, Phillips AN, Rezza G. Cozzi Lepri A, et al. Among authors: phillips an. BMJ. 1994 Dec 10;309(6968):1537-42. doi: 10.1136/bmj.309.6968.1537. BMJ. 1994. PMID: 7819892 Free PMC article.

3

Reconstitution of herpes simplex virus-specific T cell immunity in HIV-infected patients receiving highly active antiretroviral therapy.

Ramaswamy M, Waters A, Smith C, Hainsworth E, Hardy G, Johnson M, Ainsworth J, Phillips A, Geretti AM. Ramaswamy M, et al. Among authors: phillips a. J Infect Dis. 2007 Feb 1;195(3):410-5. doi: 10.1086/510623. Epub 2006 Dec 20. J Infect Dis. 2007. PMID: 17205480

4

Prevalence and predictors of antiretroviral drug resistance in newly diagnosed HIV-1 infection.

Booth CL, Garcia-Diaz AM, Youle MS, Johnson MA, Phillips A, Geretti AM. Booth CL, et al. Among authors: phillips a. J Antimicrob Chemother. 2007 Mar;59(3):517-24. doi: 10.1093/jac/dkl501. Epub 2007 Jan 9. J Antimicrob Chemother. 2007. PMID: 17213262

5

HIV-1 drug resistance in HIV-1-infected children in the United Kingdom from 1998 to 2004.

Chakraborty R, Smith CJ, Dunn D, Green H, Duong T, Doerholt K, Riordon A, Lyall H, Tookey P, Butler K, Sabin CA, Gibb D, Pillay D; Collaborative HIV Paediatric Study; UK Collaborative Group on HIV Drug Resistance. Chakraborty R, et al. Pediatr Infect Dis J. 2008 May;27(5):457-9. doi: 10.1097/INF.0b013e3181646d6f. Pediatr Infect Dis J. 2008. PMID: 18382385

6

Initiatives for developing and comparing genotype interpretation systems: external validation of existing systems for didanosine against virological response.

Assoumou L, Brun-Vézinet F, Cozzi-Lepri A, Kuritzkes D, Phillips A, Zolopa A, Degruttola V, Miller V, Costagliola D; Standardization and Clinical Relevance of HIV Drug Resistance Testing Project of the Forum for Collaborative HIV Research. Assoumou L, et al. Among authors: phillips a. J Infect Dis. 2008 Aug 15;198(4):470-80. doi: 10.1086/590156. J Infect Dis. 2008. PMID: 18598191

7

The impact of different definitions on the estimated rate of transmitted HIV drug resistance in the United Kingdom.

Green H, Tilston P, Fearnhill E, Pillay D, Dunn DT; UK Collaborative Group on HIV Drug Resistance. Green H, et al. J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):196-204. doi: 10.1097/QAI.0b013e318185725f. J Acquir Immune Defic Syndr. 2008. PMID: 18769348

8

British HIV Association Guidelines for the treatment of HIV-1-infected adults with antiretroviral therapy 2008.

Gazzard BG, Anderson J, Babiker A, Boffito M, Brook G, Brough G, Churchill D, Cromarty B, Das S, Fisher M, Freedman A, Geretti AM, Johnson M, Khoo S, Leen C, Nair D, Peters B, Phillips A, Pillay D, Pozniak A, Walsh J, Wilkins E, Williams I, Williams M, Youle M; BHIVA Treatment Guidelines Writing Group. Gazzard BG, et al. Among authors: phillips a. HIV Med. 2008 Oct;9(8):563-608. doi: 10.1111/j.1468-1293.2008.00636.x. HIV Med. 2008. PMID: 18826546 Free article. No abstract available.

9

Population trends in the prevalence and patterns of protease resistance related to exposure to unboosted and boosted protease inhibitors.

Dunn D, Geretti AM, Green H, Fearnhill E, Pozniak A, Churchill D, Pillay D, Sabin C, Phillips A; UK Collaborative Group on HIV Drug Resistance; UK Collaborative HIV Cohort Study. Dunn D, et al. Among authors: phillips a. Antivir Ther. 2008;13(6):771-7. Antivir Ther. 2008. PMID: 18839778

10

Determinants of virological failure after successful viral load suppression in first-line highly active antiretroviral therapy.

Geretti AM, Smith C, Haberl A, Garcia-Diaz A, Nebbia G, Johnson M, Phillips A, Staszewski S. Geretti AM, et al. Among authors: phillips a. Antivir Ther. 2008;13(7):927-36. Antivir Ther. 2008. PMID: 19043927

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

4,616 results

Search Page